Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
October 05, 2025 09:00 ET Â | Source: Spyre Therapeutics, Inc. WALTHAM, Mass.,…
Orano: Beginning of a New Phase for the Nurlikum Mining Joint Venture in Uzbekistan
PARIS--(BUSINESS WIRE)--Regulatory News: In September 2025, the state-owned enterprise Navoiyuran (Uzbekistan), the…
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX),…
FIA: After announcing her candidacy, Laura Villars reaches out to all member clubs
GENEVA, Sept. 24, 2025 /PRNewswire/ --Â Just days after officially announcing her candidacy…
LANZAJET AND KAZMUNAYGAS (KMG) ANNOUNCE KAZAKHSTAN’S FIRST SUSTAINABLE AVIATION FUEL PROJECT PASSES MAJOR MILESTONE AND ADVANCES TO ENGINEERING AND DESIGN PHASE
As part of New York Climate Week, LanzaJet's CEO addressed the President…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET Â | Source: C4 Therapeutics, Inc. Cemsidomide in…
Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant…
Milano Cortina 2026 ramps up excitement as Italy enters final delivery phase
17 September 2025 -Â With just 70 days to go until the Olympic…
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…